Genetics of Type 2 Diabetes in West Africans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00837122|
Recruitment Status : Recruiting
First Posted : February 5, 2009
Last Update Posted : December 20, 2017
- Type 2 diabetes (T2D) and associated complications are major contributors to the global disease burden. T2D is already a major health threat in populations in developed countries and is rapidly taking hold in the developing world.
- It is believed that understanding the complex interplay between genetic and lifestyle characteristics in the etiology of T2D and related complications will lead to the development of better preventive and therapeutic strategies. In Addition, the results of this project will facilitate our understanding of causes of diabetes in African Americans, other US and world populations
- To conduct a genome-wide association study (GWAS) to identify susceptibility genetic variants for diabetes among the Yoruba people in Ibadan, Nigeria.
- To enroll and examine 300 unrelated cases of T2D and 300 ethnicity-matched Yoruba controls.
- To conduct resequencing of positional candidate gene/loci to identify likely functional variants in a subset of the cohort.
- To conduct replication studies of the top-100 scoring variants in three independent African and European ancestry samples.
- To investigate whether diabetes-associated variants discovered in European populations increase diabetes risk in West Africans.
- Patients 25 years of age with confirmed T2D who are newly diagnosed or on treatment of Yoruba ethnicity in Ibadan, Nigeria. Control subjects are nondiabetics ethnically matched to patients.
- The study design for both patients and controls consists of the following steps:
- Discuss informed consent process and obtain signed informed consent form. Informed consent will be administered by trained clinic staff.
- Assign study ID (barcode)
- Administer questionnaires
- Obtain spot urine sample
- Measure blood pressure
- Obtain anthropometric measurements including body composition
- Perform finger prick for blood glucose level
- Obtain venous blood samples
- Perform eye examination
- On the following day, perform confirmatory blood glucose for the small subset of participants requiring confirmation of previous test result DNA extraction of stored samples will be done at either the National Institutes of Health or the laboratory in Nigeria.
- GWAS will be conducted using publicly available software packages.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||9000 participants|
|Official Title:||Genetics of Tye 2 Diabetes in Diverse Populations|
|Study Start Date :||February 3, 2009|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00837122
|Contact: Shirley Freeman||(301) firstname.lastname@example.org|
|Contact: Charles N Rotimi, M.D.||(301) email@example.com|
|University College Hospital||Recruiting|
|Principal Investigator:||Charles N Rotimi, M.D.||National Human Genome Research Institute (NHGRI)|